Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 17/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 15/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991466 | 0.80 | KIT (0.51) | KITDDR1DDR2BRAF | |
| SCHEMBL9903867 | 0.78 | KIT (0.42) | KITDDR1DDR2BRAF | |
| SCHEMBL9902904 | 0.76 | BRAF (0.46) | KITDDR1DDR2BRAF | |
| SCHEMBL9903131 | 0.76 | KIT (0.56) | KITDDR1DDR2 | |
| SCHEMBL1990213 | 0.75 | KIT (0.46) | KITDDR1DDR2BRAF | |
| SCHEMBL9902765 | 0.75 | CYP2A6 (0.53) | CYP2A6KITDDR1DDR2 | |
| SCHEMBL9902753 | 0.75 | KIT (0.46) | KITDDR1DDR2BRAF | |
| SCHEMBL9903127 | 0.75 | KIT (0.50) | KITDDR1DDR2BRAF | |
| SCHEMBL17080364 | 0.73 | EGLN2 (0.41) | KITDDR1DDR2BRAF | |
| SCHEMBL1991829 | 0.73 | KIT (0.40) | KITDDR1DDR2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | claimed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | CYP2A6 3239/4885KIT 4512/4885DDR1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.